Stephens J R, Levy R H
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle 98195.
Pharm Weekbl Sci. 1992 Jun 19;14(3A):118-21. doi: 10.1007/BF01962700.
Therapeutic use of the anticonvulsant valproate (VPA) has been associated with a rare, but severe and often fatal hepatotoxicity. Cases usually present with lethargy, anorexia, and vomiting with rapid progression to coma. Liver histopathology is characterized by steatosis with and without necrosis. In some instances only necrosis was present. Several hypotheses of pathogenesis have been postulated. These deal mainly with biochemical systems that are known to be affected by VPA, or with the possible idiosyncratic production of toxic VPA metabolites, especially delta 4-VPA. At present, no hypothesis entirely explains the diverse characteristics of the disorder.
抗惊厥药丙戊酸盐(VPA)的治疗用途与一种罕见但严重且常致命的肝毒性有关。病例通常表现为嗜睡、厌食和呕吐,并迅速发展为昏迷。肝脏组织病理学特征为伴有或不伴有坏死的脂肪变性。在某些情况下仅存在坏死。已经提出了几种发病机制假说。这些主要涉及已知受VPA影响的生化系统,或可能特异产生的有毒VPA代谢物,尤其是δ4-VPA。目前,没有一种假说能完全解释该病症的多样特征。